iMARK is based in an ISO13485-certified 130,000ft2 facility with more than 30 injection moulding presses and ISO Class 7-certified cleanroom that occupies a 15,000ft2 space.
Following the acquisition, Comar will be able to serve medical device customers by offering new cleanroom scientific injection moulding capacity and engineering expertise.
The integrated company will provide custom plastic moulding and assembly services to Comar’s medical device, diagnostic and pharmaceutical customers.
iMARK president Mark Sturtevant will continue to operate the iMARK facility and will be fully involved in serving existing and future customers of both companies.
Comar CEO Mike Ruggieri said: “We are so excited to be welcoming Mark and Linda Sturtevant and their outstanding team to the Comar organisation. They truly know how to serve their customers with parts right the first time and repeat that reliably.
“We look forward to partnering with them to better serve our current and prospective customers with new capacity and capabilities. And we look forward to continuing to acquire strategic and complementary businesses like iMARK.”
The acquisition is not expected to cause any plant closures, employee layoffs, interruptions or quality issues.
Comar runs nine manufacturing and distribution facilities across the US.
The company focuses on rigid plastic packaging technologies, including injection moulding, injection blow moulding, injection stretch blow moulding and extrusion blow moulding.